New York State Common Retirement Fund Buys 120,309 Shares of Phreesia, Inc. $PHR

New York State Common Retirement Fund boosted its position in Phreesia, Inc. (NYSE:PHR) by 727.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 136,856 shares of the company’s stock after acquiring an additional 120,309 shares during the quarter. New York State Common Retirement Fund owned 0.23% of Phreesia worth $3,219,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in PHR. Royal Bank of Canada boosted its holdings in shares of Phreesia by 208.8% in the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock worth $617,000 after purchasing an additional 16,309 shares in the last quarter. AQR Capital Management LLC lifted its position in Phreesia by 471.2% in the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after buying an additional 132,015 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Phreesia by 3.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after buying an additional 2,158 shares in the last quarter. NewEdge Advisors LLC grew its position in Phreesia by 262.7% during the first quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock valued at $395,000 after acquiring an additional 11,181 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Phreesia by 0.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock valued at $15,336,000 after purchasing an additional 2,402 shares during the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Insider Buying and Selling

In other news, insider David Linetsky sold 6,038 shares of the firm’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $98,781.68. Following the completion of the transaction, the insider directly owned 223,942 shares in the company, valued at $3,663,691.12. This trade represents a 2.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Evan Roberts sold 6,268 shares of the company’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $102,544.48. Following the completion of the transaction, the insider owned 826,554 shares in the company, valued at approximately $13,522,423.44. The trade was a 0.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 60,766 shares of company stock worth $1,013,817 over the last three months. Corporate insiders own 5.50% of the company’s stock.

Phreesia Price Performance

Shares of PHR stock opened at $12.22 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. Phreesia, Inc. has a fifty-two week low of $12.06 and a fifty-two week high of $32.76. The firm has a market cap of $736.74 million, a P/E ratio of -122.19 and a beta of 0.65. The business’s 50 day moving average price is $16.40 and its 200-day moving average price is $21.92.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The company had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. During the same quarter in the prior year, the company earned ($0.25) earnings per share. The firm’s revenue for the quarter was up 12.7% on a year-over-year basis. On average, equities research analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on PHR. DA Davidson lowered their price target on shares of Phreesia from $35.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Zacks Research cut Phreesia from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Needham & Company LLC restated a “buy” rating and set a $35.00 price target on shares of Phreesia in a research report on Monday, December 8th. Truist Financial set a $24.00 price objective on Phreesia in a research report on Thursday, January 8th. Finally, Wall Street Zen lowered Phreesia from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Seventeen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Phreesia presently has an average rating of “Moderate Buy” and a consensus price target of $29.41.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.